

**TRIMEDYNE REPORTS PROFIT FOR THE QUARTER AND SIX MONTHS ENDED  
MARCH 31, 2007; TRIMEDYNE'S 7TH CONSECUTIVE PROFITABLE QUARTER**

FOR IMMEDIATE RELEASE

CONTACT: Jeffrey Rudner  
(949) 951-3800, Ext. 285  
jrudner@trimedyne.com

May 23, 2007 – Lake Forest, CA: TRIMEDYNE, INC. (OTCBB “TMED”) today reported a profit of \$20,000 for the quarter and \$186,000 for the six-month period ended March 31, 2007. The quarter ended March 31, 2007 is the second quarter of Trimedyne’s current fiscal year and represents Trimedyne’s 7th consecutive profitable quarter. In the three and six months period of the prior year, Trimedyne’s profits were \$83,000 and \$97,000, respectively.

Revenues for the three and six-month periods ended March 31, 2007, were \$1,468,000 and \$2,893,000, respectively, compared to revenues of \$1,545,000 and \$3,330,000 in the prior year three and six-month periods. The declines in revenues were primarily due to decreases in laser sales of \$67,000 in the current quarter and \$442,000 in the current six-month period, as customers held up orders pending the availability of Trimedyne’s new, disposable VaporMAX® Side Firing Laser Fiber. This Fiber will be marketed as an accessory to Trimedyne’s Holmium lasers for the treatment of benign prostatic hyperplasia or “BPH”, commonly referred to as an enlarged prostate. BPH affects about 50% of men at age 55 and a higher percentage at later ages. The worldwide market for treating BPH is estimated to exceed \$700 million per year.

Trimedyne’s R&D expenses for the current quarter rose by \$105,000 over the prior year period. Trimedyne is concentrating its efforts on preparing for the production of a different version of its new, disposable, Side Firing Laser Fiber, which will be marketed by Boston Scientific Corporation in the United States and Japan and by Lumenis, Ltd. throughout the rest of the world for use with Lumenis’ Holmium lasers for the treatment of BPH. Shipments of the new Fiber to Boston Scientific and Lumenis are currently expected to commence in the third or fourth calendar quarter of 2007, when Boston Scientific and Lumenis complete their review of the product and Trimedyne’s quality and manufacturing processes.

Glenn D. Yeik, President of Trimedyne, said, “While the sales of lasers add significant dollars to revenues, lasers typically carry much smaller profit margins than disposable laser fibers. We remained profitable, in spite of larger R&D expenses, due to an increase in royalty payments and improved efficiencies in manufacturing fibers in Trimedyne’s new production facility. Trimedyne’s

gross profit in the current quarter was 41% of sales, versus 40% of sales in the year earlier quarter.”

Trimedyne manufactures proprietary Holmium lasers and patented fiber optic laser devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. For product, press release, financial and other information, please visit Trimedyne's website, <http://www.trimedyne.com>.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, including words like “expect”, “may”, “could” and others. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's Form 10-K-SB for the year ended September 30, 2006 and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

\* \* \* \*

TRIMEDYNE, INC.  
CONSOLIDATED BALANCE SHEET  
(UNAUDITED)

ASSETS

	March 31, 2007
-----	
Current assets:	
Cash and cash equivalents	\$ 3,747,000
Trade accounts receivable, net of allowance for doubtful accounts of \$12,000	658,000
Inventories	2,881,000
Other current assets	277,000
-----	
Total current assets	7,563,000
Note due from related party	26,000
Property and equipment, net	842,000
Other	39,000
Goodwill	544,000
-----	
	\$ 9,014,000
=====	

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:	
Accounts payable	\$ 268,000
Accrued expenses	403,000
Deferred revenue	55,000
Accrued warranty	20,000
Notes payable and current portion of long-term debt	2,000
-----	
Total current liabilities	748,000
Senior convertible secured notes due to officer	200,000
Accrued interest due to officer	121,000
Deferred rent	94,000
Long-term debt, net of current portion	1,000
-----	
Total liabilities	1,164,000
-----	
Commitments and contingencies	
Stockholders' equity:	
Preferred stock - \$0.01 par value, 1,000,000 shares authorized, none issued and outstanding	--
Common stock - \$0.01 par value; 30,000,000 shares authorized, 17,695,011 shares issued, 17,593,402 shares outstanding	178,000
Additional paid-in capital	51,022,000
Accumulated deficit	(42,637,000)
-----	
Treasury stock, at cost (101,609 shares)	8,563,000
	(713,000)
-----	
Total stockholders' equity	7,850,000
-----	
	\$ 9,014,000
=====	

TRIMEDYNE, INC.  
CONSOLIDATED STATEMENTS OF INCOME  
(UNAUDITED)

	Three Months Ended March 31,		Six Months Ended March 31,	
	2007	2006	2007	2006
Net revenues	\$ 1,468,000	\$ 1,545,000	\$ 2,893,000	\$ 3,330,000
Cost of revenues	860,000	928,000	1,639,000	2,076,000
Gross profit	608,000	617,000	1,254,000	1,254,000
Operating expenses:				
Selling, general and administrative	553,000	585,000	1,032,000	1,165,000
Research and development	255,000	150,000	413,000	295,000
Total operating expenses	808,000	735,000	1,445,000	1,460,000
Loss from operations	(200,000)	(118,000)	(191,000)	(206,000)
Other income, net	224,000	203,000	381,000	306,000
Income before provision for income taxes	24,000	85,000	190,000	100,000
Provision for income taxes	4,000	2,000	4,000	3,000
Net income	\$ 20,000	\$ 83,000	\$ 186,000	\$ 97,000
Net income per share:				
Basic	\$ 0.00	\$ 0.01	\$ 0.01	\$ 0.01
Diluted	\$ 0.00	\$ 0.01	\$ 0.01	\$ 0.01
Weighted average number of shares outstanding:				
Basic	17,532,763	14,715,580	17,019,394	14,709,969
Diluted	18,769,173	15,575,082	18,251,514	15,550,402